# Sage Cognition Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/sage-cognition-randomized-trial-evidence-review
Category: evidence-review
Summary: Sage Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomi
Last reviewed: 2026-07-28
Reviewed by: Migaku Evidence Review
# Sage Cognition Randomized Trial: What the Evidence Says

## Quick Answer

Sage Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Huntington's disease clinical trials update: October 2025 | randomized trial | 2 | 2025-11-26 | 10.1177/18796397251399751 |
| Mind the Gap: The Cognitive Blind Spot in Epilepsy | research article | 4 | 2026-01-20 | 10.1177/15357597261416742 |

## What The Sources Report

- HTT One-time bilateral intraparenchymal infusion of SPK-10001 (also known as RG6662) into the caudate and putamen, compared with placebo surgery.SPK-10001 is an engineered adeno-associated virus (AAV) vector delivering an artificial microRNA designed to selectively target humanmRNA. [Farag Mena (2025); evidence level 2]
- Up to 53 adults (aged 25-65 years) with genetically confirmed HD (CAG repeat length ≥40), evidence of striatal atrophy and preserved functional capacity (defined as UHDRS TFC ≥11) will be enrolled into the clinical trial. [Farag Mena (2025); evidence level 2]
- Cognitive clarity, improved attention, and enhanced executive control may recalibrate how individuals appraise seizure risk, mitigating anticipatory anxiety even when seizure control is suboptimal. [Zawar Ifrah (2026); evidence level 4]
- If QOL can be meaningfully improved without eliminating seizures, then epilepsy care must expand its definition of therapeutic success. [Zawar Ifrah (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For sage cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Farag Mena (2025). Huntington's disease clinical trials update: October 2025. DOI: 10.1177/18796397251399751. PMCID: PMC12847458. PMID: 41295902. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/
- Zawar Ifrah (2026). Mind the Gap: The Cognitive Blind Spot in Epilepsy. DOI: 10.1177/15357597261416742. PMCID: PMC12819126. PMID: 41574182. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ https://us.sagepub.co.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12819126/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.